IL‐18: A potential inflammation biomarker in Wiskott–Aldrich syndrome

Analysis of serum cytokine levels in Wiskott–Aldrich syndrome patients pre‐ and post‐ treatment reveals IL‐18 as a stable and reliable marker of inflammation. Definitive stem cell treatment with good myeloid correction correlates with resolution of inflammation and reduction of circulating IL‐18, hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivers, Elizabeth, Hong, Ying, Bajaj‐Elliott, Mona, Worth, Austen, Thrasher, Adrian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436742/
https://www.ncbi.nlm.nih.gov/pubmed/33448368
http://dx.doi.org/10.1002/eji.202049024
Descripción
Sumario:Analysis of serum cytokine levels in Wiskott–Aldrich syndrome patients pre‐ and post‐ treatment reveals IL‐18 as a stable and reliable marker of inflammation. Definitive stem cell treatment with good myeloid correction correlates with resolution of inflammation and reduction of circulating IL‐18, highlighting the importance of actin cytoskeletal regulation of myeloid cells in control of inflammation. [Image: see text]

Ejemplares similares